Abstract
Despite the advent of numerous new treatments for atopic dermatitis, many patients, both adults and children, are still on treatment errands and are not receiving sufficient treatment to control their disease in the long term. It is therefore important to identify patients who need systemic treatment when topical treatments are no longer suitable. The decision to initiate a systemic treatment must be based on several factors that go well beyond the marketing authorisation and reimbursement of a drug. This approach involves a multidimensional assessment of the disease’s severity, in which scores have a place if they are feasible in practice and if they take into account the patient’s perception of their symptoms and the impact of the disease on their quality of life. Shared decision-making means that the expectations of the doctor and the patient (or the patient’s family in the case of children) can be harmonised, and a suitable and realistic therapeutic objective can be defined in a collaborative manner. Identifying a patient eligible for systemic treatment at an early stage requires appropriate training in primary care (general practitioner or paediatrician) and a good city-hospital cooperation for the dermatologist or allergist in order to facilitate the patient pathway and guarantee access to «the right treatment at the right time».
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call